---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-104743"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:44:48.511699+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TransCode closes $8.5M public offering; issues 16.9M shares/pre-funded warrants at $0.51

## Summary
- Gross proceeds ~$8.5M from sale of 700K common shares and 16.2M pre-funded warrants at $0.51 per share/warrant, including partial over-allotment exercise.
- Use of proceeds for clinical trials of lead candidate TTX-MC138 and working capital.
- ThinkEquity sole book-runner; granted 45-day over-allotment option (partially exercised) plus 843K underwriter warrants at $0.6375 per share.

## SEC filing metadata
- accession: 0001104659-23-104743
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923104743/0001104659-23-104743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923104743/tm2327131d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-104743
- JSON: https://secwatch.observer/filing/0001104659-23-104743.json
- Plain text: https://secwatch.observer/filing/0001104659-23-104743.txt

## Key facts
- Material Agreements
  Transcode Therapeutics, Inc. entered into Underwriting Agreement with ThinkEquity LLC valued at approximately $8.5 million (effective 2023-09-25).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: ThinkEquity LLC
  - Value: approximately $8.5 million
  - Effective: 2023-09-25
  source text: On September 25, 2023, TransCode Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), an aggregate of (i) 700,000 shares (“Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase 16,163,000 shares of Common Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923104743/0001104659-23-104743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.